The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Checkpoint proteins are an integral part of the immune system and are used by the tumor
cells to evade immune response, which helps them grow uncontrollably. By blocking these …

Immune checkpoint inhibitors (ICIs) have heralded a new era in immunotherapy,
representing a pivotal breakthrough in cancer treatment. Their impact is profound, with ICIs …

Over the past few decades, immune checkpoint inhibitors (ICIs) have emerged as promising
therapeutic options for the treatment of various cancers. These novel treatments effectively …

Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour
immunity, can trigger neurological adverse events closely resembling paraneoplastic …

Background Lymphocyte-activation gene 3 (LAG3) is a recently discovered immune
checkpoint molecule that has been linked to immunosuppression and the advancement of …

Cancer treatments have recently shifted from broad-spectrum cytotoxic therapies to more
focused treatments, maximizing anti-cancerous activity while reducing toxicity to healthy …

Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI)
have changed the landscape of management in hepatocellular carcinoma (HCC) …

With the aging of the population, malignancies are becoming common complications in
patients with rheumatoid arthritis (RA), particularly in elderly patients. Such malignancies …